PURPOSE: Previous research incorporating yoga (YG) into radiotherapy (XRT) for women with breast cancer finds improved quality of life (QOL). However, shortcomings in this research limit the findings. PATIENTS AND METHODS: Patients with stages 0 to III breast cancer were recruited before starting XRT and were randomly assigned to YG (n = 53) or stretching (ST; n = 56) three times a week for 6 weeks during XRT or waitlist (WL; n = 54) control. Self-report measures of QOL (Medical Outcomes Study 36-item short-form survey; primary outcomes), fatigue, depression, and sleep quality, and five saliva samples per day for 3 consecutive days were collected at baseline, end of treatment, and 1, 3, and 6 months later. RESULTS: The YG group had significantly greater increases in physical component scale scores compared with the WL group at 1 and 3 months after XRT (P = .01 and P = .01). At 1, 3, and 6 months, the YG group had greater increases in physical functioning compared with both ST and WL groups (P < .05), with ST and WL differences at only 3 months (P < .02). The group differences were similar for general health reports. By the end of XRT, the YG and ST groups also had a reduction in fatigue (P < .05). There were no group differences for mental health and sleep quality. Cortisol slope was steepest for the YG group compared with the ST and WL groups at the end (P = .023 and P = .008) and 1 month after XRT (P = .05 and P = .04). CONCLUSION:YG improved QOL and physiological changes associated with XRT beyond the benefits of simple ST exercises, and these benefits appear to have long-term durability.
RCT Entities:
PURPOSE: Previous research incorporating yoga (YG) into radiotherapy (XRT) for women with breast cancer finds improved quality of life (QOL). However, shortcomings in this research limit the findings. PATIENTS AND METHODS: Patients with stages 0 to III breast cancer were recruited before starting XRT and were randomly assigned to YG (n = 53) or stretching (ST; n = 56) three times a week for 6 weeks during XRT or waitlist (WL; n = 54) control. Self-report measures of QOL (Medical Outcomes Study 36-item short-form survey; primary outcomes), fatigue, depression, and sleep quality, and five saliva samples per day for 3 consecutive days were collected at baseline, end of treatment, and 1, 3, and 6 months later. RESULTS: The YG group had significantly greater increases in physical component scale scores compared with the WL group at 1 and 3 months after XRT (P = .01 and P = .01). At 1, 3, and 6 months, the YG group had greater increases in physical functioning compared with both ST and WL groups (P < .05), with ST and WL differences at only 3 months (P < .02). The group differences were similar for general health reports. By the end of XRT, the YG and ST groups also had a reduction in fatigue (P < .05). There were no group differences for mental health and sleep quality. Cortisol slope was steepest for the YG group compared with the ST and WL groups at the end (P = .023 and P = .008) and 1 month after XRT (P = .05 and P = .04). CONCLUSION: YG improved QOL and physiological changes associated with XRT beyond the benefits of simple ST exercises, and these benefits appear to have long-term durability.
Authors: Kavita D Chandwani; Bob Thornton; George H Perkins; Banu Arun; N V Raghuram; H R Nagendra; Qi Wei; Lorenzo Cohen Journal: J Soc Integr Oncol Date: 2010
Authors: Julienne E Bower; Deborah Garet; Beth Sternlieb; Patricia A Ganz; Michael R Irwin; Richard Olmstead; Gail Greendale Journal: Cancer Date: 2011-12-16 Impact factor: 6.860
Authors: James W Carson; Kimberly M Carson; Laura S Porter; Francis J Keefe; Victoria L Seewaldt Journal: Support Care Cancer Date: 2009-02-12 Impact factor: 3.603
Authors: Alyson B Moadel; Chirag Shah; Judith Wylie-Rosett; Melanie S Harris; Sapana R Patel; Charles B Hall; Joseph A Sparano Journal: J Clin Oncol Date: 2007-09-04 Impact factor: 44.544
Authors: R M Raghavendra; R Nagarathna; H R Nagendra; K S Gopinath; B S Srinath; B D Ravi; S Patil; B S Ramesh; R Nalini Journal: Eur J Cancer Care (Engl) Date: 2007-11 Impact factor: 2.520
Authors: James W Carson; Kimberly M Carson; Laura S Porter; Francis J Keefe; Heather Shaw; Julie M Miller Journal: J Pain Symptom Manage Date: 2007-03 Impact factor: 3.612
Authors: Suzanne C Danhauer; Elizabeth L Addington; Lorenzo Cohen; Stephanie J Sohl; Marieke Van Puymbroeck; Natalia K Albinati; S Nicole Culos-Reed Journal: Cancer Date: 2019-04-01 Impact factor: 6.860
Authors: Suzanne C Danhauer; Leah P Griffin; Nancy E Avis; Stephanie J Sohl; Michelle T Jesse; Elizabeth L Addington; Julia A Lawrence; Michael J Messino; Jeffrey K Giguere; Shantae L Lucas; Susan K Wiliford; Edward Shaw Journal: J Community Support Oncol Date: 2015-04
Authors: Suzanne C Danhauer; Elizabeth L Addington; Stephanie J Sohl; Alejandro Chaoul; Lorenzo Cohen Journal: Support Care Cancer Date: 2017-01-07 Impact factor: 3.603
Authors: Alejandro Chaoul; Kathrin Milbury; Amy Spelman; Karen Basen-Engquist; Martica H Hall; Qi Wei; Ya-Chen Tina Shih; Banu Arun; Vicente Valero; George H Perkins; Gildy V Babiera; Tenzin Wangyal; Rosalinda Engle; Carol A Harrison; Yisheng Li; Lorenzo Cohen Journal: Cancer Date: 2017-09-20 Impact factor: 6.860
Authors: Heather Greenlee; Melissa J DuPont-Reyes; Lynda G Balneaves; Linda E Carlson; Misha R Cohen; Gary Deng; Jillian A Johnson; Matthew Mumber; Dugald Seely; Suzanna M Zick; Lindsay M Boyce; Debu Tripathy Journal: CA Cancer J Clin Date: 2017-04-24 Impact factor: 508.702
Authors: Ann M Berger; Kathi Mooney; Amy Alvarez-Perez; William S Breitbart; Kristen M Carpenter; David Cella; Charles Cleeland; Efrat Dotan; Mario A Eisenberger; Carmen P Escalante; Paul B Jacobsen; Catherine Jankowski; Thomas LeBlanc; Jennifer A Ligibel; Elizabeth Trice Loggers; Belinda Mandrell; Barbara A Murphy; Oxana Palesh; William F Pirl; Steven C Plaxe; Michelle B Riba; Hope S Rugo; Carolina Salvador; Lynne I Wagner; Nina D Wagner-Johnston; Finly J Zachariah; Mary Anne Bergman; Courtney Smith Journal: J Natl Compr Canc Netw Date: 2015-08 Impact factor: 11.908